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Background: Homocysteine (Hcy) is an independent cardiovascular risk factor; however, in diabetes, the role of 
tissue Hcy leading to cardiac dysfunction is unclear.  
Aims: To determine whether tissue Hcy caused endothelial-myocyte uncoupling and ventricular dysfunction in 
diabetes.  
Methods: Diabetes was created in C57BL/6J male mice by injecting 65 mg/kg alloxan. To reverse diabetic compli-
cations, ciglitazone (CZ) was administered in the drinking water. Plasma glucose, Hcy, left ventricular (LV) tissue 
levels of Hcy and nitric oxide (NO) were measured. Glomerular filtration rate (GFR) was measured by inu-
lin-FITC. Endothelial-myocyte coupling was measured in cardiac rings. In vivo diastolic relaxation and LV di-
ameters were measured by a Millar catheter in LV and by M-mode echocardiography, respectively.  
Results: Plasma glucose, GFR and LV tissue Hcy were increased in diabetic mice and were normalized after CZ 
treatment; whereas, elevated plasma Hcy level remained unchanged with or without CZ treatment. NO levels in 
the LV were found inversely related to tissue Hcy levels. Attenuated endothelial-myocyte function in diabetic 
mice was ameliorated by CZ treatment. Cardiac relaxation, the ratio of LV wall thickness to LV diameter was 
decreased in diabetes, and normalized after CZ treatment.   
Conclusion: CZ normalized LV tissue levels of Hcy and ameliorated endothelial-myocyte coupling; therefore, 
specifically suggest the association of LV tissue Hcy levels with impair endothelial-myocyte function in diabetes. 
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1. Introduction 
Sixteen percent of the myocardial mass is capil-
laries and capillaries are made up of lumen and en-
dothelium [1]. The capillary endothelium is embedded 
in the muscle, and plays an important role in myocar-
dial diastolic relaxation [2]. Nitric oxide (NO) from the 
endocardial endothelium contributes to the regulation 
of myocyte relaxation [3]. A gradient of NO concen-
tration (i.e. high in endocardium and low in midmyo-
cardium) has been depicted [3] that is consistent with 
the notion that there is more capillary endothelium in 
the endocardium than in epi- or mid-myocardium. The 
importance of endocardial endothelium in cardiac 
contraction and relaxation is illustrated by the attenu-
ated responses to CaCl2 and acetylcholine in the en-
dothelium-denuded myocardium [4, 5]. In addition, 
the contractile response to endothelin-1 was increased 
in endothelium-denuded myocardial rings [6]. Thus, 
the paracrine modulation of cardiac myocyte function 
by endothelial cell factors is an important mechanism 
contributing to the overall regulation of cardiac con-
tractile function, both in physiological and pathologi-
cal states [7].  
  Homocysteine (Hcy) is a non-protein, sul-
fur-containing amino acid formed during the metabo-
lism of methionine in the body. Reduced kidney func-
tion and volume retention has been associated with 
Hcy accumulation in the plasma and tissues [8], which 
leads to endothelial damage [9].  
  In an experimental study of insulin resistant 
(obese) type 2 diabetes, an improvement of insulin Int. J. Biol. Sci. 2008, 4 
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resistance with intravenous insulin over a period of 17 
days did not alter Hcy levels [10]. However, several 
lines of evidence suggest a higher risk of heart disease 
associated with 5 µmol/L (plasma) increases in Hcy 
among a diabetic group compared to a non-diabetic 
group. Therefore, it is important to keep track of Hcy 
levels in diabetics. In a diabetic rabbit model, concen-
trations of Hcy in the physiologic range dramatically 
inhibited arterial nitric oxide formation, but had no 
effect in non-diabetic animals [11]. Although in diabe-
tes, nitric oxide concentrations decreases, the rela-
tionship between Hcy and insulin is ambiguous. 
However, the role of Hcy in impairment of endothelial 
nitric oxide metabolism is unequivocal.  
  Renal hyper filtration in a diabetic subject with-
out nephropathy was associated with increased Hcy 
catabolism and clearance [12]. Insulin reduces the cir-
culating levels of other amino acids [13] and perhaps, 
promotes the uptake of Hcy into tissues which result in 
increased tissue Hcy [8]. The peroxisome prolifera-
tor-activated receptor-γ (PPARγ) that belongs to the 
family of nuclear receptor is associated with type-2 
diabetes and is directly related to blood glucose [14]. 
Although renal clearance plays a significant role in 
Hcy clearance, the contributions of high glucose, insu-
lin and other factors in tissue Hcy accumulation are 
very important but not well studied. In the present 
study we tested our hypothesis that increase in tissue 
Hcy level, but not the plasma Hcy level, instigates 
endothelial-myocyte uncoupling. This leads to cardiac 
dysfunction in diabetic-cardiomyopathy.  
2. Materials and Methods   
2.1. Diabetic mouse model  
The mice were divided into five groups of six as 
described below. To create diabetes, alloxan (A) 
[Sigma Chemical Co, 65 mg/kg body weight] was in-
jected by a single dose in the tail vein, and mice were 
sacrificed at 0, 1, and 10 weeks after alloxan injection. 
In this protocol, 0 wk was considered as the 
non-diabetic control. Mice were anesthetized with tri-
bromoethanol (100 mg/kg i.p.), which has minimal 
effects on cardiovascular function in mice [15]. To in-
duce PPARγ, 10 wks after alloxan, ciglitazone (CZ, 
CalBiochem Corp) 8 µg/ml was administered in the 
drinking water and the mice were sacrificed at 12 and 
16 weeks (n=6 in each group). The non-diabetic con-
trols for 1 and 10 weeks mice were used to compare 
with diabetic mice for 1 and 10 weeks. The diabetic 
CZ-treated animals of 12 and 16 weeks were compared 
with younger diabetic animals (i.e. before the start of 
the CZ treatment). Animal room temperature was 
maintained between 22oC and 24oC. A 12-hour 
light-dark cycle was maintained by artificial illumina-
tion. The investigation conforms to the Guide for the 
Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 
85-23, revised 1985). All animal procedures were re-
viewed and approved by the Institutional Animal Care 
and Use Committee of the University Of Louisville 
School Of Medicine. The animals were fed standard 
c h o w  a n d  w a t e r  a d  l i b i t u m .  N o  m o r t a l i t y  w a s  o b -
served at the end of the study protocol.  
  The amount of CZ (8 µg/ml) was soluble in 
aqueous conditions and was based on the fact that the 
binding constant between ciglitazone and PPARγ is in 
the micromolar range [16]. Based on the assumption 
that mice have a blood volume of ~2 ml and drink ~5 
ml water/day, each ingested ~2 mg/kg/day CZ. This 
produced a blood concentration of ~32 µMole/L, 
which is enough to saturate most binding sites on 
PPAR. In humans, 100 mg/day PPAR agonist has a 
potent effect [17]. To determine whether the A and CZ 
treatment causes change in food and water intake, 
food and water intake were measured every 2-days 
during the treatment period. To determine if there was 
peroxisome proliferation, the livers were weighed at 
the end of the protocol. CZ (like other PPARγ agonists) 
may cause hepatotoxicity at higher dose [18], and 
hepatomegaly may be reflective of other pathologies 
rather than peroxisome proliferation. Therefore, we 
assessed microscopical observations of liver tissues at 
low doses of chronic CZ treatment. We observed hy-
perplasia and proliferation of the peroxisomes; how-
ever, the data is not shown in the present report.  
2.2. Glucose and Hcy  
To measure plasma glucose and Hcy, blood was 
collected in heparinized tubes from anesthetized mice. 
Glucose was measured using a Bio-Rad glucose 
measurement kit. Hcy was separated by HPLC and 
detected by a spectrophotometer [8].   
2.3. Tissue NO and Hcy  
Fresh tissue was homogenized in 50 mM Tris-Cl 
(pH 7.4) buffer. The levels of NO were measured by 
Griess method. Total, protein-bound and free Hcy 
were measured as described [8].  
2.4. Glomerular filtration rate (GFR)  
To demonstrate that levels of Hcy corroborate 
with renal glomerular filtration rate (GFR), GFR was 
measured using inulin-FITC as a marker in mice [19]. 
In brief, 0.3 mg/25 gram body weight inulin-FITC in-
fused by Mini-osmotic pump model 2001D (alzet), 8 
µl/hour, 1 day (I. P.), prior to placement of mice in 
metabolic cages. For a span of 24 hours, urine was 
collected. The levels of inulin in blood and urine were 
measured from a standard plot generated using inu-Int. J. Biol. Sci. 2008, 4 
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lin-FITC as the standard in the spectrofluorometer 
with emission at 530 nm and excitation at 488 nm. The 
control plasma and urine were used as references 
when inulin was measured in plasma and urine of 
inulin-FITC injected mice. To establish steady-state 
plasma inulin levels over the collection period and to 
determine variations among different mice, plasma 
inulin levels were measured in each animal. There 
were no significant differences in plasma inulin levels 
observed between different mice. The inulin excretion 
rate, µl/min/g of kidney weight was measured from 
each mouse.  
2.5. Echocardiography and hemodynamic parameters  
To determine in vivo cardiac diastolic relaxation, 
a Millar catheter was inserted into the LV through the 
right common carotid artery and M-mode echocardi-
ography (Philips) was performed. The aortic blood 
pressure (BP), heart rate (HR), and systolic and dia-
stolic blood pressure (SBP & DBP) were measured. 
After arterial pressure measurements, the catheter was 
advanced to the LV and LVP, EDP and -dP/dt were 
measured. Pulsatile arterial pressure signal was ana-
lyzed by a computer using customized software (Mi-
cro-Med Corp).   
2.6. Preparation of endothelin-1, acetylcholine, nitro-
prusside, bradykinin, and alloxan solutions  
The concentrations of endothilin-1, acetylcholine, 
nitroprusside, bradykinin, and alloxan were based on 
weight measurements. All dilutions from stock solu-
tions were made in phosphate-buffered saline (PBS), 
prior to the experiment. PBS was used as a vehicle 
control.  
2.7. Endocardial endothelial-myocyte function  
To determine specific regional differences in 
contractile function, rings were prepared to include, or 
to exclude, the homogenous or non-homogeneous re-
gions of the transmural myocardial wall [6]. The "deli" 
shape LV rings were mounted in a tissue myobath. 
One of the two mounted wires was connected to a 
force transducer. The ring was stretched and brought 
to a resting tension at which 10 nM endothelin-1 (ET-1) 
was added. At the maximum ET-1 contraction, ace-
tylcholine (endothelial-dependent) or nitroprusside 
(endothelial-independent)  was added. To minimize 
the differences due to orientation of cardiac muscle, 
the rings were rotated 90o and contraction was meas-
ured again. The average of these two contractions was 
recorded. The % relaxation was calculated based on 
100% contraction to 10 nM ET-1 and dose-response 
curves were generated. To avoid ischemia, oxygen at 
20 psi was continuously bubbled through the myo-
bath. This was sufficient to penetration of cardiotonic 
agent [6]. The experiments were completed within 40 
min during that time there was minimal injury due to 
ischemia [6].  
2.8. Western blot analysis of PPARγ  
The levels of PPARγ in the LV tissue homoge-
nates was determined using anti-PPARγ antibody 
(Cyncam Inc). The secondary rabbit alkaline phos-
phatase conjugate anti-body was used as the detection 
system. To establish the specificity of PPARγ, 
anti-PPARγ-agarose conjugate was used to im-
muno-precipitate the total PPARγ content in the sam-
ples prior to loading it onto the gel/blot.  
2.9. Statistical analysis  
Values are given as mean ± SEM from n=6 in each 
group. Differences between groups were evaluated by 
using a two-way ANOVA, followed by the Bonferroni 
post hoc test [20], focusing on the respective effects of 
diabetes. The results of the 4 comparisons by Bon-
ferroni test are reported as: *, compared to 0 wk. **, 
compared to 10 wks. A p < 0.05 was considered sig-
nificant.  
3. Results   
3.1. Levels of PPARγ in diabetes  
The levels of PPARγ were decreased in chronic 
diabetic model. The treatment with CZ mitigated this 
decrease (Fig. 1).   
 
Fig. 1. Western blot analysis of cardiac PPAR-γ: LV tissue 
homogenates were blotted with anti-PPAR-γ antibody. Mice at 0 
(n=6), 1 (n=6) and 10 (n=6) weeks (wks). Other alloxan-treated 
mice received ciglitazone (CZ) and hearts were collected at 12 
(n=6) and 16 (n=6) wks. Bar graphs represent the scanned val-
ues of PPAR-γ. * indicates p<0.005 when compared with 0 wk. Int. J. Biol. Sci. 2008, 4 
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3.2. Plasma glucose and homocysteine (Hcy)  
Plasma glucose levels increased within one week 
after alloxan injection. The levels were decreased after 
treatment with ciglitazone (CZ) (Fig 2A). Plasma Hcy 
levels were increased 10 weeks after alloxan injection, 
and remained elevated up to 16 weeks, with or with-
out the CZ treatment (Fig. 2B). The observed results 
suggested severe diabetic complications in mice at 10 
weeks compared to the non-diabetic controls. The mice 
recovered significantly from diabetic complications 
when treated with CZ as compared to untreated mice 
at 16 weeks. These results suggested that PPARγ ago-
nist CZ ameliorated the hyperglycemia, and had no 




Fig. 2. Plasma levels of glucose and homocysteine (Hcy): (A): 
Mice were treated with alloxan (A) and blood was collected 
from deeply anesthetized mice at 0 (n=6), 1 (n=6) and 10 (n=6) 
weeks (wks). Other alloxan-treated mice received ciglitazone 
(CZ) and blood was collected at 12 (n=6) and 16 (n=6) wks. 
Levels of glucose were compared to 0 wk, * indicates p<0.01 
comparing to 0 wk. ** indicates p<0.02 comparing to 10 wks. 
(B): Plasma Hcy was separated with HPLC and measured by a 
spectrophotometer. * indicates p<0.005 when compared with 0 
wk. Note that CZ ameliorated hyperglycemia. However, CZ did 
not change the levels of Hcy. 
3.3. Glomerular filtration rate (GFR)  
There was hyperfiltration at the onset of diabetes. 
GFR decreased significantly by the tenth week after 
alloxan injection compared to controls at 0 week, sug-
gesting renal impairment in this model of diabetes. 
Treatment with CZ ameliorated the decrease in GFR 
during diabetes (Fig. 3). These results suggest that in 
chronic alloxan-induced diabetes, initially there is hy-
perfiltration, followed by hypo-filtration.  
 
Fig. 3. Glomerular filtration rate (GFR): Mice were treated with 
alloxan (A) and GFR was measured at 0 (n=6), 1 (n=6) and 10 
(n=6) weeks (wks). Prior to placement in metabolic cages, 0.3 
milligrams of inulin-FITC/25 gram of body weight was placed I. 
P. by osmotic minipump, and 24-h urine was collected. Other 
alloxan-treated mice that received ciglitazone (CZ) were placed 
in metabolic cages, and urine was collected at 12 (n=6) and 16 
(n=6) wks. A standard curve was generated using inulin-FITC 
as standard and measuring fluorescence at 530 nm, when ex-
citing at 488 nm. Urine inulin-FITC was measured using ref-
erence-urine from mice that were not given inulin. GFR was 
expressed as µl/min/g of kidney weight. *, p<0.02 compared to 
0 wk; **, p<0.05 when compared to 1 wk. Note that in this 
model of diabetes, initially there is hyper-filtration followed by 
hypo-filtration. 
3.4. Heart tissue levels of Hcy and nitric oxide (NO)  
Cardiac tissue Hcy levels were increased one 
week after alloxan-injection and remained elevated 
(Fig. 4A). Treatment with CZ ameliorated the increase 
in cardiac Hcy levels; however, in the present report no 
specific effects of CZ on Hcy metabolism were studied. 
Under the same conditions, NO levels inversely mir-
rored Hcy levels (Fig. 4B). These results and results 
from the previous section suggest that in diabetics, 
initially there is no change in plasma levels of Hcy (Fig. 
2B); however, cardiac Hcy levels are increased within 1 
week of diabetes induction (Fig. 4A) and are inversely 
related to cardiac NO generation (Fig. 4B).  
3.5. Endothelial-myocyte uncoupling in diabetes  
The relaxation to acetylcholine was attenuated in 
cardiac rings from wild type mice treated with alloxan 
at 1 and 10 weeks. Treatment with ciglitazone amelio-
rated the alloxan-diabetes mediated endothe-
lial-dependent myocyte uncoupling, at 12 and 16 
weeks (Fig. 5B). The relaxation to bradykinin was also 
attenuated in cardiac rings prepared from mice treated 
with alloxan at 1 week. At week 10, bradykinin in-
duced contraction instead of relaxation. Treatment 
with ciglitazone restored bradykinin-mediated cardiac 
relaxation, at 12 and 16 weeks (Fig. 5C). The relaxation 
to nitroprusside was attenuated in cardiac rings from Int. J. Biol. Sci. 2008, 4 
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mice treated with alloxan at 1 and 10 weeks. Treatment 
with CZ ameliorated the endothelial-dependent myo-
cyte uncoupling, and decreased nitroprusside re-
sponses in this model of alloxan-induced type 1 dia-
betes (Fig. 5D). The above results suggest that alloxan 
impaired NO-dependent and independent cardiac 
relaxation. Treatment with CZ ameliorated this im-
pairment. Alloxan-diabetes also decreased the endo-
thelium-derived hyperpolarizing factor 
(EDHF)-mediated (bradykinin-dependent), cardiac 
relaxation. The PPARγ agonist CZ ameliorated the 
decreased EDHF-mediated cardiac relaxation.  
3.6. In vivo cardiac relaxation and contraction 
The rate of cardiac diastolic relaxation was de-
creased at week(s) 1 and 10 after alloxan injection (Fig. 
6A, B). Treatment with CZ ameliorated this cardiac 
diastolic impairment (Fig. 6A, B). The myocyte systolic 
contraction was decreased significantly at 10 weeks 
after alloxan injection (Fig. 6C) compared to 0 wk. 
However, CZ treatment normalized myocyte contrac-
tile dysfunction (Fig. 6C) at 12 and 16 wks. Together, 
these results suggest that endothelial-dependent car-
diac diastolic relaxation and myocyte contraction were 
impaired in diabetes and that the PPARγ agonist ame-
liorated this impairment. 
 
Fig. 4. Heart tissue levels of Hcy and nitric oxide: (A): In 
anesthetized mice that were treated with alloxan (A), hearts 
were removed at 0 (n=6), 1 (n=6) and 10 (n=6) weeks (wks). 
The remaining alloxan-treated mice received ciglitazone (CZ) 
and hearts were removed at 12 (n=6) and 16 (n=6) wks. Left 
ventricle (LV) homogenates were prepared. Total Hcy was 
extracted, separated by HPLC, and quantitated by a spectro-
photometer. Hcy was expressed as ng/mg of protein. *, p<0.01 
when compared to 0 wk; **, p<0.01 when compared to 10 wks. 
(B): Total nitrate/nitrite was measured by Griess method. Nitric 
oxide levels were expressed as nMole/L of LV homogenate. 
Identical amounts of total protein were used. *, p<0.02 when 
compared to 0 wk; **, p<0.005 when compared to 10 wks. Note 






Fig. 5. Cardiac coupling responses to cardiotonic agents: (A): a 
typical contractile response to 10 nM endothelin-1 (ET-1) and 






tylcholine (ACH) in a ring prepared from mice at 0 time of 
alloxan treatment. (B): Contractile responses of LV rings from 
alloxan-treated mice at 0, 1, 10 weeks and from alloxan-treated 
mice that were given CZ at 12 and 16 weeks. Rings were pre-
contracted with ET-1. The relaxation to ACH was calculated as 
% of the ET-1 contraction. Each data point is mean ± SEM of at 
least 6 animals. (C): Different doses of bradykinin (BK) were 
added to the bath. The relaxation to BK was calculated as % of 
the ET-1 contraction. Each data point is mean ± SEM of at least 
6 animals. (D):  Different doses of nitroprusside (Npr) were 
added to the bath. The relaxation to Npr was calculated as % of 
the ET-1 contraction. Each data point is mean ± SEM of at least 
6 animals. Note that endothelial-dependent and independent 
relaxation is impaired in diabetes and CZ ameliorates this im-







Fig. 6. (A): Typical LV pressure wave from a mouse 10 wks 
after alloxan treatment. EDP indicates point of end-diastolic 
pressure. LVPmax indicates maximum LV pressure. The –dP/dt 
indicates derivative of fall in pressure during LV relaxation. (B): 
Since the rate of LV relaxation (-/dP/dt) is afterload-dependent, 
-dP/dt was normalized with mean arterial pressure (MAP): In 
deeply anesthetized mice, a Millar catheter was inserted into the 
LV through the right common carotid artery and LV variables 
were measured at 0, 1, and 10 wks of alloxan (A) treatment. In 
other alloxan-treated mice, CZ was administered and LV vari-
ables were measured at 12 and 16 wks. Each bar represents 
mean ± SEM (n=6). *, p<0.001 when compared to 0 wk. **, 
p<0.005 when compared to 10 wks. Note that LV diastolic 
relaxation was impaired and treatment with CZ ameliorated the 
diastolic dysfunction in diabetes. (C): Since the LV systolic 
contraction (LVP/LVW): In deeply anesthetized mice, a Millar 
catheter was inserted into the LV through the right common 
carotid artery and LV pressure was measured. Each bar repre-
sents mean ± SEM (n=6). *, p<0.002 when compared to 0 wk. 
**, p<0.001 when compared to 10 wks.  
 
The M-mode echocardiographic data indicated an 
increase in cardiac diameter and decrease in LV wall 
thickness at 1 and 10 wks of diabetes. Treatment with 
CZ normalized the LV wall and diameters (Fig. 7). 
Also, an increase in cardiac diameter and decrease in 
LV wall thickness at 1 and 10 weeks may suggest di-
lated cardiomyopathy. Additionally, to compare be-
tween groups the gravimetric and hemodynamic pa-
rameters from experimental and control groups are 







Fig. 7. M-Mode ECHO at 0 and 10 wks after al-
loxan injection, and at 16 wks after alloxan-injected 
mice treated with ciglitazone (CZ). Bar graph 
represents mean+SEM of LVwall/LVdiameter. 
* 
p<0.002 when compared to 0 wk; 
** p<0.001 when 
compared to 10 wks. Note that LV dilatation oc-
curred in diabetes and was ameliorated by CZ 
treatment. 
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Table 1. Body weight (BW), mouse urinary protein (MUP, μg/day/kg), left ventricular (LV), right ventricular (RV), and kidney 
weight (KW) in grams of wildtype mice treated with alloxan. The hemodynamic parameters: mean arterial pressure (MAP, mmHg), 
systolic blood pressure (SP, mmHg), diastolic blood pressure (DP, mmHg), and heart rate (HR, beats/min) were measured by a 
Millar catheter in right carotid artery. LV pressure (LVPmax), end-diastolic pressure (EDP) and first derivative of fall in LV pressure, 
-dP/dt, were measured by a catheter in LV (n=6 in each group). 
 
 
4. Discussion   
  The hyper-, regular-, and de-
creased-renal-filtration during early, intermediate, and 
late phases of diabetes [21], influence the levels of Hcy 
[12]. An accumulating body of evidence indicates 
weaker endothelial-dependent relaxation in type 1 and 
t y p e  2  d i a b e t e s  m e l l i t u s  ( D M )  [ 2 2 - 2 4 ] .  O t h e r s  h a v e  
shown increased endothelial-dependent relaxation, 
followed by a phase where relaxation returns to nor-
mal, and then a final phase of impaired relaxation [21]. 
We have shown structural glomerular expansion and 
glomerular collapse in early versus late phases of hy-
pertension [25]. Also, the later phase is associated with 
wrinkling and thickening of the glomerular capillary 
wall [25]. Nevertheless, the renal mechanism of hyper- 
and hypo-filtration in early versus late phases of dia-
betes is unclear. In the present study, we demonstrated 
that although there is no change in plasma Hcy levels, 
the cardiac Hcy levels were robustly increased in the 
early phase of diabetes. Although increased levels of 
Hcy in diabetes are associated with decreased renal 
clearance in the later phase of diabetes, increased glu-
cose levels in DM may impair Hcy metabolism and 
may also cause an increase in Hcy levels. Therefore, an 
initial increase in Hcy levels may be attributed to im-
paired Hcy metabolism by glucose. However, the later 
synergism between the increase in glucose with im-
paired renal function may cause a robust increase in 
Hcy levels in plasma as well as in tissues. We and 
others have suggested an inverse relationship between 
the levels of endothelial nitric oxide and levels of Hcy 
[6, 11]. This may lead to decreased coupling between 
endothelium and myocyte during cardiac relaxation. 
To reverse diabetic complications in diabetes, CZ was 
administered after the creation of diabetes. The results 
suggested that CZ ameliorated the diabetes-mediated 
impaired cardiac relaxation. This improvement in car-
diac relaxation is most likely, in part, by decreasing 
cardiac tissue levels of Hcy, as increased level of Hcy is 
known for endothelial injury and dysfunction [26].  
 Plasma glucose decreased by CZ treatment. This 
is not unexpected with PPARγ agonists. We used 10 
week diabetic mice to compare diabetic mice treated 
with CZ at 12 and 16 weeks. The results suggested 
mitigation in impairments in GFR, myocyte function Int. J. Biol. Sci. 2008, 4 
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and cardiomyocyte relaxation by CZ treatment when 
compared with 12 and 16 untreated diabetic control 
mice.  
  Clinical studies have suggested that patients on 
PPAR agonists have improved cardiovascular function 
in diabetes [27]; however, the levels of Hcy did not 
decrease. In fact, Hcy levels were slightly increased. 
Previously we demonstrated that Hcy competes with 
PPAR ligands [28]. Therefore, PPAR agonists displace 
the Hcy and increases plasma Hcy. In the present 
study we suggest that although PPAR agonist has no 
effect on plasma Hcy, the levels of cardiac Hcy were 
decreased by PPAR agonist. In addition, the levels of 
glucose were decreased by PPAR agonist. Glucose 
decreases the activity of CBS (cystathion-
ine-β-synthase) and MTHFR (methylenetetrahydro-
folate reductase), enzymes responsible for Hcy clear-
ance, and may also contribute to an increase in cardiac 
Hcy. In addition, mammalian endothelial cells are 
lacking the CBS enzyme [9]. Therefore, endothelial 
cells are the prime target for Hcy-toxicity. 
 Since capillary endothelial cells are embedded in 
the muscle, the contribution of endothelium to myo-
cyte relaxation is the least studied. Our study demon-
strated that although both plasma and myocardial 
tissue level of Hcy increased in alloxan-induced dia-
betes; the tissue level of Hcy attenuated by PPARγ 
agonist (CZ)-treated diabetic mice, without any altera-
tion of plasma Hcy level. The decreased myocardial 
tissue level of Hcy was found to improve myocardial 
relaxation as demonstrated by in vitro study. For ex-
ample, with cardiac ring preparation we have studied 
both endothelial dependent and independent myo-
cardial relaxation in vitro. For endothelial dependent 
cardiac relaxation we used acetylcholine and bra-
dykinin. Acetylcholine works through release of en-
dothelial-dependent NO generation, and bradykinin 
works on blood vessels through the nitric oxide and 
endothelial-derived hyperpolarizing factor. Both fac-
tors have shown endothelial dependent relaxation was 
attenuated in diabetic rings; however, endothelial in-
dependent vascular relaxing factor sodium nitropru-
side also attenuated cardiac relaxation in vitro. Nitro-
pruside induces vascular relaxation through direct 
generation of NO, which is independent of endothe-
lium. Therefore, it was expected to relax cardiac ring in 
our present study. On the contrary, we have seen an 
opposite effect. This is we believe, at least in part, due 
to endothelial-myocyte uncoupling which did not al-
low nitropruside generated NO to travel through the 
disrupted matrix between endothelial-myocyte. Thus, 
we have seen attenuated relaxation. These results con-
firmed the uncoupling of endothelial-myocyte in dia-
betes; CZ however, improved the relaxation in cardiac 
rings suggesting the attributed role of CZ in endothe-
lial-myocyte recoupling in diabetes. This study clearly 
demonstrated that endocardial endothelium contrib-
ut es t o  c ardi ac  rel ax at io n  an d is  af fec t ed b y  v ar io us 
cardiotonic agents, at least partly, in controlling myo-
cyte function.  
  It is worthy to mention that in our experimental 
groups we had additional diabetic animals of 12 and 16 
weeks. These animals did not show any further 
changes of our tested parameters reported here com-
pared to 10 weeks diabetic control animals. Therefore, 
we did not present these study groups in this report. 
Thus, the comparison between diabetic animals and 
ciglitazone-treated diabetic animals is performed by 
comparing ciglitazone-treated animals (at 12 and 16 
weeks) with 10 weeks diabetic animals (i.e. before start 
of the ciglitazone treatment), assuming that 10 weeks 
diabetic animals are a common representative of all 
three control diabetic animal groups, i.e. 10, 12 and 16 
weeks. Additionally, we used LV pressure and pres-
sure derived parameters to describe LV performance 
without the implementation of simultaneously derived 
LV volume data. Only when determining end-systolic 
(ESPVR) and end-diastolic (EDPVR) pressure-volume 
relationships a reliable description of LV performance 
can be given. We considered these were certain limita-
tions of our present report.  
  In summary, our present study demonstrated 
that decrease renal function and increase LV tissue 
Hcy were observed in diabetic mice. This increase in 
tissue levels of Hcy were associated with endothe-
lial-myocyte uncoupling that resulted attenuated LV 
function both in vivo and in vitro. PPARγ agonist CZ 
normalized LV tissue levels of Hcy and ameliorated 
endothelial-myocyte coupling. Thus, this study high-
lighted the importance of tissue Hcy in dia-
betic-induced renal failure and emphasizes the poten-
tial role of CZ to ameliorate Hcy-induced cardiac 
dysfunction in diabetes.   
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